Latest Information Update: 14 Mar 2006
At a glance
- Originator Roche
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Type-2 diabetes mellitus in Switzerland (unspecified route)
- 19 Apr 2004 Preclinical trials in Type-2 diabetes mellitus in Switzerland (unspecified route)